Phase I trial of bruceantin.

Abstract

Bruceantin was administered to 33 patients with advanced solid tumors or hematologic neoplasms. The schedule consisted of four weekly iv injections at one dose level followed by a 2-week "no-treatment" period; this program was repeated every 6 weeks. A total of 156 weekly injections were given over a dose range of 0.8-8.5 mg/m2. Systolic and diastolic hypotension was dose-related and dose-limiting at doses of greater than or equal to 6.0 mg/m2. Transient febrile reactions were dose-related. Gastrointestinal toxicity was commonly observed but was not dose-limiting. There was no hematologic or renal toxicity; hepatic toxicity was subclinical and reversible. Of 18 patients evaluable for antitumor response one patient with adenocarcinoma of the cervix experienced a less than 50% disease regression lasting 10 months and one patient with pleural mesothelioma experienced disease stabilization lasting 4 months. A phase II study of bruceantin is recommended at a starting dose of 5.5 mg/m2 weekly for 4 weeks as a 4-hour iv infusion repeated at 6-week intervals.

• Authors: M B Garnick, R H Blum, G P Canellos, R J Mayer, L Parker, A T Skarin, F P Li, I C Henderson, E Frei 3rd
• Journal: Cancer treatment reports (Cancer Treat Rep) 1979 Nov-Dec Vol. 63 Issue 11-12 Pg. 1929-32 ISSN: 0361-5960 [Print] United States
• PMID: 526926 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents, Phytogenic
• Pyrans
• Quassins
• Glaucarubin
• bruceantin

Topics

• Adenocarcinoma (drug therapy)
• Adolescent
• Adult
• Aged
• Antineoplastic Agents, Phytogenic (administration & dosage, therapeutic use, toxicity)
• Child
• Child, Preschool
• Digestive System (drug effects)
• Drug Evaluation
• Female
• Fever (chemically induced)
• Glaucarubin (administration & dosage, analogs & derivatives, therapeutic use, toxicity)
• Humans
• Hypotension (chemically induced)
• Liver (drug effects)
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Pyrans (therapeutic use)
• Quassins
• Uterine Cervical Neoplasms (drug therapy)